Fintel reports that on September 30, 2026, Stifel initiated coverage of Achieve Life Sciences (NASDAQCM:ACHV) (DB:SP4P) with a Buy recommendation.
Achieve Life Sciences, Inc., based in the United States, operates within the biopharmaceutical industry focused on developing and commercializing novel treatments for addiction and related disorders. One of its key projects involves the development of cytisinicline, a plant-based alkaloid with a high-binding affinity to the nicotinic acetylcholine receptor, aimed at aiding smoking cessation. The company is advancing its clinical development, actively engaging in multiple phase 3 trials to further evaluate the efficacy and safety of cytisinicline for broad therapeutic use.
Prior to this rating action, the stock recorded a pre-action close of $7.69 on September 29, 2026, which is also the latest close price. This follows a one-week price change of -5.30% from a baseline close of $8.12 on September 22, 2026, and a one-month price change of -5.06% from a baseline close of $8.10 on August 28, 2026. Achieve Life Sciences reported its latest earnings on August 11, 2026, with an actual earnings per share (EPS) of -0.8, compared to an estimated EPS of -0.1582. Both actual revenue and estimated revenue for the period were $0.00.
Separately from Stifel's individual action, the current consensus target mean for the stock was $14.11 as of September 15, 2026, representing an implied change of +83.48% from the market price. The current consensus target median was $12.75. This mean target remains unchanged from the prior consensus target mean of $14.11 recorded on August 28, 2026, showing a consensus target revision of 0.00%.
In terms of broader analyst sentiment, the current recommendation period as of September 1, 2026, shows a total of 17 recommendations, consisting of 3 strong buy, 13 buy, 1 hold, 0 sell, and 0 strong sell ratings. This represents 94.1% positive recommendations, 5.9% hold recommendations, and 0.0% negative recommendations. This is a shift from the prior recommendation period as of August 1, 2026, which had a total of 15 recommendations, including 3 strong buy, 11 buy, 1 hold, 0 sell, and 0 strong sell ratings, representing 93.3% positive, 6.7% hold, and 0.0% negative recommendations.
Recent analyst actions
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.